Immunogenicity Testing Evolved

The success of protein-based drugs hinges on identifying potential immune system reactions early in development. EpiScreen® 2.0 represents a groundbreaking advancement in immunogenicity testing, offering unparalleled sensitivity without radioactivity. This innovative approach leverages flow cytometry to meticulously dissect the immune response, pinpointing the specific cell types involved.

Unlike traditional assays, EpiScreen® 2.0 goes beyond basic proliferation analysis. It empowers researchers to delve into the mechanism of action by monitoring activation markers, providing a comprehensive picture of the immune response. This data-rich platform empowers researchers to make informed decisions and select the most promising protein therapeutic candidates, ultimately accelerating drug development and ensuring a smoother path to market.

Ensure the success of your protein therapeutics with EpiScreen® 2.0. Learn more about this innovative immunogenicity testing technology.